Published in Science · View the paper (DOI)
Researchers have developed a CRISPR-Cas9 gene editing system to treat Duchenne muscular dystrophy (DMD), a debilitating genetic disease. By deleting exon 23 and restoring dystrophin protein levels, the therapy improved muscle function in mice with DMD, including cardiac and pulmonary health.
Coverage from 2 institutions